Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report-Reference-Cited by-同舟云学术

Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report

Published:2016-01-27 Issue:1 Volume:41 Page:104-105
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Lambert Kuhn E.¹,Levêque D.¹,Lioure B.²,Gourieux B.¹,Bilbault P.³

Affiliation:

1. Pharmacy; Strasbourg University Hospital; Strasbourg France

2. Hematology/Oncology Department; Strasbourg University Hospital; Strasbourg France

3. Emergency Department; Strasbourg University Hospital; Strasbourg France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12355/fullpdf

Reference9 articles.

1. Imbruvica ® summary of product characteristics October 2015 http://ec.europa.eu/health/documents/community-register/2015/20150703132326/anx_132326_fr.pdf

2. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy;Honigberg;Proc Natl Acad USA,2010

3. Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men;Scheers;Drug Metab Dispos,2015

4. Stable isotope-intravenous microdose for absolute bioavailability and effects of grapefruit juice on ibrutinib in healthy subjects;Vries;Br J Clin Pharmacol,2015

5. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies;Marostica;Cancer Chemother Pharmacol,2015

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool;Clinical Pharmacokinetics;2024-08

3. A Structure‐Activity Investigation of the Fungal Metabolite (−)‐TAN‐2483B: Inhibition of Bruton's Tyrosine Kinase;Chemistry – A European Journal;2024-05-31

4. Cytochrome P450 3A2 and PGP-MDR1-Mediated Pharmacokinetic Interaction of Sinapic Acid with Ibrutinib in Rats: Potential Food/Herb–Drug Interaction;Processes;2022-05-26

5. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors;Circulation Research;2021-06-11